Mineralys Therapeutics
MLYS | NASDAQ
$14.53
-$0.80 (-5.22%)
At close: Nov 16, 2026, 4:00 PM ET
$14.29
-$0.24 (-1.65%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Mineralys Therapeutics Company Profile
Company profile explainedCompany Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Key Executives
| Name | Position |
|---|---|
| Jon Congleton | President, Chief Executive Officer & Director |
| Adam Scott Levy | Chief Financial Officer & Secretary |
| Jeffrey A. Munsie | Chief Legal Officer |
| Brian Taylor Slingsby | Founder & Executive Director |
| Danielle Mahoney | Senior Vice President of Quality Assurance |
| Eric J. Warren | Chief Commercial Officer |
| James J. Ferguson FACC | Chief Medical Officer |
| Jessica Ibbitson | Executive Vice President of Operations |
| Michael Tortorici | Senior Vice President of Translational Medicine |
| Robert McKean | Senior Vice President of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 20, 2026 | 4 | Filing |
| Oct 20, 2026 | 3 | Filing |
| Oct 20, 2026 | 4 | Filing |
| Oct 20, 2026 | 3 | Filing |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Sep 24, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
Mineralys Therapeutics
| Country | United States |
| IPO Date | Feb 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Jon Congleton |
Contact Details
150 N. Radnor Chester Rd. Radnor,
Pennsylvania 19087 United States
Stock Details
| Ticker Symbol | MLYS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001933414 |
| CUSIP Number | 603170101 |
| ISIN Number | US6031701013 |
| SIC Code | 2834 |
Recent News
- 8 days ago / globenewswire.comMineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
- 12 days ago / seekingalpha.comMineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)
- 12 days ago / marketbeat.comWhat Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call
- 12 days ago / seekingalpha.comMineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript
- 13 days ago / globenewswire.comMineralys Therapeutics to Participate in Upcoming Investor Conferences
- 19 days ago / globenewswire.comMineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
- 20 days ago / globenewswire.comMineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
- 25 days ago / globenewswire.comMineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
- 28 days ago / globenewswire.comMineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
- 1 month ago / globenewswire.comMineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Add to Watchlist
Select watchlists to add or remove MLYS